Tumors of the uterine isthmus: Clinicopathologic features and immunohistochemical characterization of p53 expression and hormone receptors

International Journal of Gynecological Pathology

Volumn 16, Issue 1, 1997, Pages 38-44

  Jacques, Suzanne M ^a,b   Qureshi, Faisal ^a   Ramirez, Nilsa C ^a   Malviya, Vinay K ^a   Lawrence, W Dwayne ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HUTZEL HOSPITAL   (United States)

Author keywords

Endometrium; Gynecologic malignancy; Uterine isthmus

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ESTROGEN RECEPTOR; MITOMYCIN C; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CASE REPORT; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL;

EID: 0030992647     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199701000-00007     Document Type: Article

References (26)

1. Silverberg SG, Kurman RJ. Tumors of the uterine corpus and gestational trophoblastic disease. In: Atlas of tumor pathology. Third series, fasc 3. Washington, D.C.: Armed Forces Institute of Pathology, 1992:47-90.
2. Hachisuga T, Kaku T, Enjoji M. Carcinoma of the lower uterine segment. Clinicopathologic analysis of 12 cases Int J Gynecol Pathol 1989;8:26-35.
3. Hendrickson MR, Kempson RL. Uterus and fallopian tubes. In: Sternberg SS, ed. Histology for pathologists. New York: Raven Press, 1992:797-834.
4. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
5. Lane DP. On the expression of the p53 protein in human cancer. Mol Biol Rep 1994;19:23-9.
6. Chambers JT, MacLusky N, Eisenfield A, Kohorn EI, Lawrence R, Schwartz PE. Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer Gynecol Oncol 1988;31:65-77.
7. Geisinger KR, Homesley HD, Morgan TM, Kute TE, Marshall RB. Endometrial adenocarcinoma. A multiparameter Clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors. Cancer 1986;58:1518-25.
8. Geisinger KR, Marshall RB, Kute TE, Homesley HD. Correlation of female sex steroid hormone receptors with histologic and ultrastructural differentiation in adenocarcinoma of the endometrium. Cancer 1986;58:1506-17.
9. Palmer DC, Muir IM, Alexander AI, Cauchi M, Bennett RC, Quinn MA. The prognostic importance of steroid receptors in endometrial carcinoma. Obstet Gynecol 1988;72:388-93.
10. Segreti EM, Novotny DB, Soper JT, Mutch DG, Creasman WT, McCarty KS. Endometrial cancer: histologic correlates of immunohistochemical localization of progesterone receptor and estrogen receptor. Obstet Gynecol 1989;73:780-5.
11. Deligdisch L, Holinka CF. Progesterone receptors in two groups of endometrial carcinoma. Cancer 1986;57:1385-8.
12. Jacques SM, Qureshi F, Lawrence WD. Surface epithelial changes in endometrial adenocarcinoma: diagnostic pitfalls in curettage specimens. Int J Gynecol Pathol 1995;14:191-7.
13. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer 1987;60:2035-41.
14. Fanning J, Evans MC, Peters AJ, Samuel M, Harmon ER, Bates JS. Endometrial adenocarcinoma histologic subtypes: clinical and pathologic profile. Gynecol Oncol 1989;32:288-91.
15. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium. II. Papillary adenocarcinoma: a clinical pathologic study of 46 cases. Am J Clin Pathol 1982-77:534-40.
16. Sivridis E, Buckley CH, Fox H. The prognostic significance of lymphatic vascular space invasion in endometrial adeno-carcinoma. Br J Obstet Gynaecol 1987;94:991-4.
17. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40: 55-65.
18. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
19. Deligdisch L, Cohen CJ. Histologic correlates and virulence implications of carcinoma associated with adenomatous hyperplasia. Cancer 1985;56:1452-5.
20. Christopherson WM, Connelly PJ, Alberhasky RC, Carcinoma of the endometrium. V. An analysis of prognosticator in patients with favorable subtypes and stage I disease. Cancer 1983;51:1705-9.
21. Robboy SJ, Bradley R. Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy. Obstet Gynecol 1979;54:269-77.
22. Beckner ME, Mori T, Silverberg SG. Endometrial carcinoma: nontumor factors in prognosis. Int J Gynecol Pathol 1985;4:131-45.
23. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-74.
24. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
25. Jiko K, Tsuda H, Sato S, Hirohashi S. Pathogenetic significance of p53 and c-Ki-ras gene mutation and human papillomavirus DNA integration in adenocarcinoma of the uterine cervix and uterine isthmus. Int J Cancer 1994;59:601-6.
26. Kurman RJ, Norris HJ, Wilkinson E. Tumors of the cervix, vagina, and vulva. In: Atlas of tumor pathology. Third series, fasc 4. Washington, D.C.: Armed Forces Institute of Pathology, 1992:37-128.